BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Other Events
Item 8.01. Other Information.

On May3, 2018, BioDelivery Sciences International, Inc. (the “Company”) issued a press release announcing its receipt of a notice from Broadfin Capital, LLC (together with its affiliates, “Broadfin”) of its intention to nominate certain individuals to stand for election to the Company’s Board of Directors (the “Board”) at the 2018 annual meeting of shareholders (the “Annual Meeting”). The Company will present its formal recommendation regarding director nominations to the Board in its definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission. The Company has not yet scheduled its Annual Meeting, and will provide shareholders with the Company’s proxy materials in connection with the Annual Meeting, including a white proxy card, in due course. A copy of the press release is attached as Exhibit99.1 hereto.

Important Additional Information

The Company intends to file a proxy statement and an accompanying WHITE proxy card with the SEC in connection with the solicitation of proxies for the Annual Meeting (the “Proxy Statement”). The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. Information regarding the names of the Company’s directors and executive officers and their respective interests in the Company by security holdings or otherwise is set forth in the Company’s 2017 Annual Report on Form 10-K, filed with the SEC on March15, 2018. To the extent holdings of such participants in the Company’s securities have changed since the amounts described in the 2017 Annual Report, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of the Board for election at the Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders will be able to obtain a copy of the definitive proxy statement and other documents filed by the Company free of charge from the SEC’s website, www.sec.gov. Company shareholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to BioDelivery Sciences International, Inc., 4131 ParkLake Ave., Suite 225, Raleigh, North Carolina 27612, Attn: Investor Relations, or from the Company’s website, www.bdsi.com.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, the press release included herein, and any statements of representatives and partners of the Company related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,”

“potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Annual Meeting as described in the attached press release) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

BIODELIVERY SCIENCES INTERNATIONAL INC Exhibit
EX-99.1 2 d772904dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital RALEIGH,…
To view the full exhibit click here

About BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.